Prolight Diagnostics publishes investorletter for January 2026

About this update from Prolight Diagnostics Ab

The investor letter outlines that Prolight has continued to make important progress in the development of the Psyros platform. Progress in cartridge manufacturing scale-up, alongside continued refinement of the instrument design, further strengthens the platform as the company prepares for the commercial launch.The investor letter is available via the attached file or on the company’s website:https://prolightdx.com/en/mediaeng/investor-letters/For further information, please contact:Ulf Bladin, CEOE-mail:Phone: +46 73 582 39 87Company website:www.prolightdx.comAbout UsProlight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.Attachments

View stock analysis, news, and events for Prolight Diagnostics Ab